The Nature of Progression in Parkinson’s Disease: An Application of Non-Linear, Multivariate, Longitudinal Random Effects Modelling
Explore this paper's citation graph
Summary
The usefulness of non-linear, multivariate, longitudinal random effects modelling for studying the temporal and spatial aspects of the progression of Parkinson’s disease is demonstrated and provides important biological insights into the pathogenesis of PD, as well as its preclinical aspects.
- Type
- article
- Published
- 2013-10-18
- Cited by
- 36
- References
- 35
- Access
- Open access
- OpenAlex
- https://openalex.org/W24204641
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:6579160
Keywords
Public health, Medicine
References
- Book Review: Statistical methods for rates and proportions, 3rd edition
- Levodopa and the progression of Parkinson's disease.
- Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes.
- Striatal subregional 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease: A two‐year follow‐up study
- The Impact of Parkinson’s Disease on Health Status, Health Expenditures, and Productivity
- Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis.
- Nonlinear mixed effects models for repeated measures data.
- In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease
- Age‐specific progression of nigrostriatal dysfunction in Parkinson's disease
- Invited Article: Functional imaging in Parkinson disease
- How common are the “common” neurologic disorders?
- Physical performance of a positron tomograph for brain imaging with retractable septa.
- Functional Imaging in Parkinson's Disease
- Non‐linear random effects model for multivariate responses with missing data
- NONLINEAR MODELS FOR REPEATED MEASUREMENT DATA.
- Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.
- Parkinson's disease: in vivo assessment of disease progression using positron emission tomography.
- Random-effects models for longitudinal data.
- PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.
- Changes in network activity with the progression of Parkinson's disease.
Cited by
- Change in Motor and Nonmotor Symptoms Severity in a “Real-Life” Cohort of Subjects with Parkinson's Disease
- Calculating clinical progression rates in Parkinson's disease: methods matter.
- Automated Neuromelanin Imaging as a Diagnostic Biomarker for Parkinson's Disease
- The Effect of MSCs Derived from the Human Umbilical Cord Transduced by Fibroblast Growth Factor-20 on Parkinson's Disease
- A REVIEW OF DISEASE PROGRESSION MODELS OF PARKINSON'S DISEASE AND APPLICATIONS IN CLINICAL TRIALS
- Therapeutic Effects of CUR-Activated Human Umbilical Cord Mesenchymal Stem Cells on 1-Methyl-4-phenylpyridine-Induced Parkinson's Disease Cell Model
- Subtypes evaluation of motor dysfunction in Parkinson's disease using neuromelanin-sensitive magnetic resonance imaging.
- Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers
- Striatal molecular imaging of presynaptic markers
- Prolonged Dysfunction of Astrocytes and Activation of Microglia Accelerate Degeneration of Dopaminergic Neurons in the Rat Substantia Nigra and Block Compensation of Early Motor Dysfunction Induced by 6-OHDA
- Striatal dopamine in Parkinson disease: A meta‐analysis of imaging studies
- PET Imaging in Movement Disorders
- Validation of diffusion tensor imaging measures of nigrostriatal neurons in macaques
- Mathematical Biology Models of Parkinson's Disease
- Age and time course of long-term motor and nonmotor complications in Parkinson disease
- Increased energetic demand supported by mitochondrial electron transfer chain and astrocyte assistance is essential to maintain the compensatory ability of the dopaminergic neurons in an animal model of early Parkinson's disease.
- Clinical progression in Parkinson’s disease with features of REM Sleep Behavior Disorder: a population-based longitudinal study
- Dopamine D3 receptor: a neglected participant in Parkinson Disease pathogenesis and treatment?
- Parkinson’s disease laterality: a 11C-PE2I PET imaging study
- The D1/D5 dopamine partial agonist PF-06412562 in advanced-stage Parkinson’s disease: a feasibility study
Related papers
No related papers recorded.